Richard T. Pines | Principal
Mr. Pines joined Athyrium in 2008 and currently serves as a Principal.
Mr. Pines expertise lies in sourcing and identifying attractive investment opportunities through his
deep network of contacts within the healthcare industry.
From sourcing, to negotiating, to structuring, to executing, to monitoring, Mr. Pines
has been involved in every stage of the investment process on numerous structured transactions.
While at Lehman Brothers
, Mr. Pines
had substantial involvement in the equity and structured investments life sciences portfolio.
Representative structured investments include companies such as Jazz Pharmaceuticals
, ISTA Pharmaceuticals
, Nektar Therapeutics
Representative structured investments include companies such as Sequenom
, Incyte Corporation
, Acorda Therapeutics
, Penwest Pharmaceuticals
Prior to Lehman, he
was an Analyst in Credit Suisse's
Investment Banking Division focused on healthcare clients.
Mr. Pines worked in a traditional healthcare coverage role before moving to a product group called the Buyside Insights Group, which provided strategic insights to the firm's clients utilizing a value-based framework.
Mr. Pines graduated with a B.S. in both Accounting and Finance from Indiana University in 2001.